TransMedics topped ‘ambitious buyside expectations,’ says Morgan Stanley

Morgan Stanley says Q2 represented “another strong quarter” from TransMedics, with a beat across essentially all core lines, topping “what we think were ambitious buyside expectations.” Second half guidance implies about 52% growth, which the firm thinks is “probably conservative, leaving some further upside to numbers,” adds the analyst, who has an Equal Weight rating and $145 price target on TransMedics shares.